Syndax outlines 2026 operating expense target of approximately $400M as Revuforj expands in NPM1 (NASDAQ:SNDX)

Syndax (SNDX) Q1 2026 earnings call recap: Revuforj & Niktimvo sales, transplant headwinds, cash runway, and 2026 catalysts—read now.

You are being redirected to the original discussion. Please continue if you want to read the full post.

You will be redirected in 3 seconds.